| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
| ln Vitro |
In neurons, it has been demonstrated that 1,3-Dicaffeoylquinic Acid increases neuronal cell viability against Aβ(42) toxicity in a concentration-dependent manner. While stimulating its upstream tyrosine kinase A (Trk A), 1,3-dicaffeoylquinic acid activates extracellular regulated protein kinase 1/2 (Erk1/2) and phosphoinositide 3-kinase (PI3K)/Akt. The augmentation of inactivating phosphorylation of glycogen synthase kinase 3β (GSK3β) and the control of the expression of apoptosis-related protein Bcl-2/Bax are linked to the anti-apoptotic potential of 1,3-dicaffeoylquinic acid [2]. In OGD/reperfusion injury, 1,3-dicaffeoylquinic acid (10 μM, 20 μM, 50 μM, and 100 μM) can prevent GSH consumption and greatly increase cell viability prior to OGD/reperfusion. In OGD/reperfusion-treated astrocytes, 1,3-dicaffeoylquinic acid causes Nrf2 nuclear translocation and raises GCL activity; however, this effect is lost in Nrf2 siRNA-transfected cells [3].
|
|---|---|
| ln Vivo |
In Wistar rats, 1-O-ABL and 1,3-dicaffeoylquinic acid (32.0 mg/kg, orally) are absorbed very quickly. 1-O-ABL and 1,3-dicaffeoylquinic acid have maximal plasma concentrations of 19.1 ± 6.9 ng/mL and 44.5 ± 7.1 ng/mL, respectively [1].
|
| References |
|
| Additional Infomation |
1,3-Dicaffeoylquinic acid has been reported in Mikania hirsutissima, Aster indicus, and other organisms with data available.
|
| Molecular Formula |
C25H24O12
|
|---|---|
| Molecular Weight |
516.4509
|
| Exact Mass |
516.126
|
| CAS # |
19870-46-3
|
| Related CAS # |
Cynarin;30964-13-7
|
| PubChem CID |
6474640
|
| Appearance |
White to yellow solid powder
|
| Density |
1.6±0.1 g/cm3
|
| Boiling Point |
819.9±65.0 °C at 760 mmHg
|
| Flash Point |
278.1±27.8 °C
|
| Vapour Pressure |
0.0±3.1 mmHg at 25°C
|
| Index of Refraction |
1.719
|
| LogP |
1.64
|
| Hydrogen Bond Donor Count |
7
|
| Hydrogen Bond Acceptor Count |
12
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
37
|
| Complexity |
887
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
O(C(/C(/[H])=C(\[H])/C1C([H])=C([H])C(=C(C=1[H])O[H])O[H])=O)[C@@]1(C(=O)O[H])C([H])([H])[C@]([H])([C@]([H])([C@@]([H])(C1([H])[H])OC(/C(/[H])=C(\[H])/C1C([H])=C([H])C(=C(C=1[H])O[H])O[H])=O)O[H])O[H]
|
| InChi Key |
YDDUMTOHNYZQPO-PSEXTPKNSA-N
|
| InChi Code |
InChI=1S/C25H24O12/c26-15-5-1-13(9-17(15)28)3-7-21(31)36-20-12-25(24(34)35,11-19(30)23(20)33)37-22(32)8-4-14-2-6-16(27)18(29)10-14/h1-10,19-20,23,26-30,33H,11-12H2,(H,34,35)/b7-3+,8-4+/t19-,20-,23-,25+/m1/s1
|
| Chemical Name |
(1S,3R,4R,5R)-1,3-bis[[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy]-4,5-dihydroxycyclohexane-1-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~193.63 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.84 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.84 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (4.84 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9363 mL | 9.6815 mL | 19.3630 mL | |
| 5 mM | 0.3873 mL | 1.9363 mL | 3.8726 mL | |
| 10 mM | 0.1936 mL | 0.9681 mL | 1.9363 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT02621060 | COMPLETEDWITH RESULTS | Drug: Placebo Drug: Chlorogenic acid |
Impaired Glucose Tolerance | University of Guadalajara | 2015-09 | Phase 2 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
